ទំព័រដើម › ជំងឺ Multiple Myeloma › កូឡូរ៉ាដូ › Denver
ការសាកល្បងគ្លីនិកសម្រាប់ ជំងឺ Multiple Myeloma នៅក្នុង Denver, CO
ការសិក្សាចំនួន 27 សម្រាប់ ជំងឺ Multiple Myeloma កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Denver (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
កំពុងជ្រើសរើសដំណាក់កាល 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
កំពុងជ្រើសរើសដំណាក់កាល 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 3
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Colorado Blood Cancer Institute, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
កំពុងជ្រើសរើសដំណាក់កាល 3
- CBCI, Colorado Blood Cancer Institute, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
កំពុងជ្រើសរើសដំណាក់កាល 3
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
កំពុងជ្រើសរើសដំណាក់កាល 1
- Colorado Blood Cancer Institute, Denver
ការសាកល្បងសម្រាប់ ជំងឺ Multiple Myeloma នៅក្នុងទីក្រុងផ្សេងទៀត
- New York City, NYការសិក្សា 60
- Boston, MAការសិក្សា 42
- Atlanta, GAការសិក្សា 42
- Houston, TXការសិក្សា 38
- Durham, NCការសិក្សា 37
- Nashville, TNការសិក្សា 32
- Rochester, MNការសិក្សា 24
- St. Louis, MOការសិក្សា 24
- Columbus, OHការសិក្សា 24
- Baldwin Park, CAការសិក្សា 23
- Edison, NJការសិក្សា 22
- Chicago, ILការសិក្សា 22
ការសិក្សាផ្សេងទៀតនៅក្នុង Denver
- មហារីកដែលរីករាលដាលការសិក្សា 29
- មហារីកទ្រូងការសិក្សា 29
- Non-Small Cell Lung Cancerការសិក្សា 27
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 23
- មេឡាណូម៉ាការសិក្សា 19
- មហារីកតូចការសិក្សា 19
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 18
- មហារីកស៊ុតការសិក្សា 16
- មហារីកសួតការសិក្សា 16
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 15
- Non-Hodgkin Lymphomaការសិក្សា 14
- មហារីកតំបក់ការសិក្សា 13
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។